


Peptide Early Discovery Service

Peptide Hit Discovery


WuXi AppTec provides multiple approaches to discover peptide hits, including DNA-Encoded Library (DEL) and display technologies. Peptide DELs are synthesized through chemical reactions, while display technologies utilize biological synthesis. The combination of DEL and display technologies allows clients to explore vast chemical space.

Peptide DNA-Encoded library (DEL)



Solution DEL

10^{11}



On-bead DEL

10^6

- High **backbone and side chain diversity**
- Incorporation of **abundant unnatural AAs** and **cyclization reactions**
- 'Permeable peptide' properties
- Highly **customizable**
- **Affinity-based** screening
- **Large** diversity
- **Functional-based & phenotypic cellular** screening

Oral Peptide & Delivery


Initial Hit Finding & Hit-to-Lead Optimization

Display Technologies



Phage Display

10^9



mRNA Display

$> 10^{12}$

- High throughput decoding and *in silico* techniques enhanced
- **Natural amino acids** dominate
- Compatible with **cellular selection** and ***in vivo* selection**
- **Larger, polar peptides**
- **Flexible** choice in peptide length
- Incorporation of **limited unnatural AAs**, more **cyclization reactions** than phage
- Compatible with **cellular selection**

Delivery


Initial Hit Finding

Bicyclic peptides constrained on a molecular scaffold not provided


Off-the-shelf & Highly Customizable Peptide Libraries

Peptide DEL

Off-the-Shelf Collection (300+ Billion):



Linear libraries



Cyclic libraries

Small cyclic libraries

Well-validated Tools for Peptide DEL Customization:


- **1,400+** validated natural and unnatural AAs
- **1000+** α -AAs with diverse side chains (D/L ratio 3:4)
- **300+** non-alpha AAs with diverse backbones
- **10%** AAs with α N-alkylation
- **9 types** of cyclization strategies established
- Peptide fragment (**3~5 AAs**) condensation

Peptide Phage Display



Linear Peptide:


- X7, X12 (commercial)
- X9, X30 (customized)



Cyclic Peptide:

- CX7C, CX13C (customized)
- CX4CX9 (customized)

mRNA Display



Cyclic Library Design

AUG UGC (NNK)_n UGC (GGC AGC)₃
 Met Cys (NNK)_n Cys (Gly Ser)₃
 CXnC, n=6-15

Peptide Hit-to-Lead Optimization

Bioassay Platform for Peptide Profiling

	Binding/PPI	Permeability*	Stability*	Functionality	Specificity/Toxicity
Biophysics	☑				
Biochemistry	☑	☑	☑	☑	☑
Structural Biology	☑				
Cell Biology		☑	☑	☑	☑
ADME		☑	☑		☑
DMPK		☑	☑	☑	☑

*Specific assessments required for peptides in the early stage, e.g.: Aggregation, GI digestion, Circulating stability, Formulation stability

Peptide Modeling:

- Virtual screening
- Virtual residue / alanine scan
- Binding mode and hotspot prediction
- Machine learning
- Molecular dynamics

Peptide Conjugation:

Linker synthesis & payload modification
Unnatural AA Availability: 3000+ Fmoc-AA catalog products & customized synthesis

Peptide Synthesis: Linear, cyclic peptides and peptidomimetics

Showcase of Integrated Peptide Discovery


Cyclic Peptide for Protein-Protein Interaction Disruption

ACS Medicinal Chemistry Letters

pubs.acs.org/acsmchemlett


Letter

DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor



- UNP-6457, a neutral nonapeptide discovered in **cyclic peptide DEL**, inhibits MDM2-p53 interaction with an IC_{50} of **8.9 nM**


Novel Peptide for Endocytosis Receptor-based Delivery



- 4 weeks** DEL screening identified a novel peptide ($EC_{50}=0.91 \mu M$) binding to specific tumor-cell for endocytosis
- DEL hits contain **pre-optimized** site for conjugation

Peptide Discovery Using Phage Display with Decoding


PCSK9 - Dose response Phage ELISA



Top peptide hits clusters at 3rd round panning

- 3 rounds panning with 3 NEB linear and cyclic peptide libraries (10^9 each) completed within **5 weeks**
- High throughput decoding** improves screening efficiency and provides abundant data which is compatible with **in silico clustering**

Customized DEL for Peptide Optimization



www.wuxibiology.com

Contact Us

BD USA: mahnaz_arjomand@wuxiapptec.com
 BD EU/UK/Israel: dave_madge@wuxiapptec.com

BD China: xu_longji@wuxiapptec.com
 BD Japan: fumio_ito@wuxiapptec.com
 BD Korea: sycho@wuxiapptec.com